Moonlight AI raises $3.3M to spot cancer biomarkers from routine blood slides
What's the deal? Moonlight AI, a Swiss startup building image analysis software for clinical diagnostics, has closed a $3.3M seed round. The company uses computer vision to detect genomic biomarkers and complex disease signatures directly from routine blood and cytology smear images — eliminating the need for costly, time-consuming genomic sequencing.
"Our technology enables labs to generate actionable, immediate results from slides they already use in their core workflows," said Christian Ruiz, chief executive officer and co-founder.
Why now? Precision oncology depends on genomic data, but Next-Generation Sequencing (NGS) remains a bottleneck. It is expensive and slow. Moonlight AI's approach sidesteps that problem entirely: it extracts genomic insights from images that haematology labs already produce, requiring no new hardware or manual processes.
The seed funding will go toward expanding the company's proprietary technology and scaling its diagnostic capacity for cancer patients worldwide.
What could go wrong? AI-powered diagnostics face steep regulatory hurdles to achieve clinical-grade certification across different markets. Convincing hospitals and labs to trust algorithmic readings for cancer treatment decisions is no small ask — especially in a field where false positives or negatives carry life-or-death consequences.
The signal: This raise reflects a broader wave of AI startups targeting the gap between what genomic medicine promises and what clinical labs can actually deliver today. Rather than replacing expensive sequencing outright, tools like Moonlight AI's offer a faster, cheaper first pass — potentially democratising access to precision oncology beyond well-funded research hospitals.
Read more: startupticker.ch
